1H-NMR based metabonomic profiling of human esophageal cancer tissue

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Wang, Liang ^a   Chen, Jie ^a   Chen, Longqi ^a   Deng, Pengchi ^b   bu, Qian ^a   Xiang, Pu ^a   Li, Manli ^a   Lu, Wenjie ^a   Xu, Youzhi ^a   Lin, Hongjun ^a   Wu, Tianming ^a   Wang, Huijuan ^a   Hu, Jing ^a   Shao, Xiaoni ^a   Cen, Xiaobo ^a   Zhao, Ying Lan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

1H NMR; Human esophageal cancer; Metabonomic profiling

Indexed keywords

4 AMINOBUTYRIC ACID; ACETIC ACID; ADENOSINE PHOSPHATE; BIOLOGICAL MARKER; CHOLINE; CREATINE; CREATININE; FATTY ACID; FORMIC ACID; GLUCOSE; NICOTINAMIDE ADENINE DINUCLEOTIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL MEMBRANE; CELL PROLIFERATION; DOWN REGULATION; ENERGY; ESOPHAGUS CANCER; FATTY ACID METABOLISM; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METABOLISM; METABOLITE; METABOLOMICS; PRINCIPAL COMPONENT ANALYSIS; PROTON NUCLEAR MAGNETIC RESONANCE; SEPARATION TECHNIQUE; UPREGULATION; CASE CONTROL STUDY; ESOPHAGUS; ESOPHAGUS TUMOR; METABOLOME; MIDDLE AGED; MUCOSA; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; MIDDLE AGED; MUCOUS MEMBRANE; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84875687724     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-25     Document Type: Article

References (58)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29. 10.3322/caac.20138, 22237781.
2. Hirst J, Smithers BM, Gotley DC, Thomas J, Barbour A. Defining cure for esophageal cancer: Analysis of actual 5-year survivors following esophagectomy. Ann Surg Oncol 2011, 18:1766-1774. 10.1245/s10434-010-1508-z, 21213056.
3. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009, 27:5062-5067. 10.1200/JCO.2009.22.2083, 19770374.
4. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007, 25:3719-3725. 10.1200/JCO.2006.10.4760, 17704421.
5. Ajani JA. Carcinoma of the esophagus: is biology screaming in my deaf ears?. J Clin Oncol 2005, 23:4256-4258. 10.1200/JCO.2005.12.911, 15781878.
6. Hsu WH, Hsu PK, Hsieh CC, Huang CS, Wu YC. The metastatic lymph node number and ratio are independent prognostic factors in esophageal cancer. J Gastrointest Surg 2009, 13:1913-1920. 10.1007/s11605-009-0982-8, 19672664.
7. Tomizawa Y, Wang KK. Screening, surveillance, and prevention for esophageal cancer. Gastroenterol Clin N 2009, 38:59-73.
8. Tew WP, Kelsen DP, Ilson DH. Targeted therapies for esophageal cancer. Oncologist 2005, 10:590-601. 10.1634/theoncologist.10-8-590, 16177283.
9. Wang DH, Souza RF. Biology of Barrett's esophagus and esophageal adenocarcinoma. Gastrointest Endosc Clin N Am 2011, 21:25-38. 10.1016/j.giec.2010.09.011, 3052949, 21112495.
10. Ekman S, Bergqvist M, Heldin CH, Lennartsson J. Activation of growth factor receptors in esophageal cancer-implications for therapy. Oncologist 2007, 12:1165-1177. 10.1634/theoncologist.12-10-1165, 17962610.
11. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189. 10.1080/004982599238047, 10598751.
12. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant Mol Bio 2002, 48:155-171.
13. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002, 1:153-162. 10.1038/nrd728, 12120097.
14. Claudino WM, Quattrone A, Biganzoli L, Pestrin M, Bertini I, Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol 2007, 25:2840-2846. 10.1200/JCO.2006.09.7550, 17502626.
15. Yang J, Xu G, Hong Q, Liebich HM, Lutz K, Schmülling RM, Wahl HG. Discrimination of Type 2 diabetic patients from healthy controls by using metabonomics method based on their serum fatty acid profiles. J Chromatogr B 2004, 813:53-58.
16. Xue R, Lin Z, Deng C, Dong L, Liu T, Wang J, Shen XA. Serum metabolomic investigation on hepatocellular carcinoma patients by chemical derivatization followed by gas chromatography/mass spectrometry. Rapid Commun Mass Sp 2008, 22:3061-3068.
17. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Beal MF. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008, 131:389-396. 10.1093/brain/awm304, 18222993.
18. Shi C, Wu C, Cao A, Sheng HZ, Yan X, Liao M. NMR-spectroscopy-based metabonomic approach to the analysis of Bay41-4109, a novel anti-HBV compound, induced hepatotoxicity in rats. Toxicol Lett 2007, 173:161-167. 10.1016/j.toxlet.2007.07.010, 17826925.
19. Wei L, Liao P, Wu H, Li X, Pei F, Li W, Wu Y. Toxicological effects of cinnabar in rats by NMR-based metabolic profiling of urine and serum. Toxicol Appl Pharm 2008, 227:417-429.
20. Gowda G, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D. Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn 2008, 8:617-633. 10.1586/14737159.8.5.617, 18785810.
21. Pan Z, Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem 2007, 387:525-527. 10.1007/s00216-006-0687-8, 16955259.
22. Cao Z, Wu LP, Li YX, Guo YB, Chen YW, Wu RH. Change of choline compounds in sodium selenite-induced apoptosis of rats used as quantitative analysis by in vitro 9.4 T MR spectroscopy. World J Gastroentero 2008, 14:3891-3896.
23. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, Wu CL. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res 2005, 65:3030-3034.
24. Van Asten JJ, Cuijpers V, Hulsbergen-van De Kaa C, Soede-Huijbregts C, Witjes JA, Verhofstad A, Heerschap A. High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies. Magn Reson Mater Phy 2008, 21:435-442.
25. Piotto M, Moussallieh FM, Dillmann B, Imperiale A, Neuville A, Brigand C, Bellocq JP, Elbayed K, Namer I. Metabolic characterization of primary human colorectal cancers using high resolution magic angle spinning 1H magnetic resonance spectroscopy. Metabolomics 2009, 5:292-301.
26. Astrakas LG, Zurakowski D, Tzika AA, Zarifi MK, Anthony DC, De Girolami U, Tarbell NJ, Black PM. Noninvasive magnetic resonance spectroscopic imaging biomarkers to predict the clinical grade of pediatric brain tumors. Clin Cancer Res 2004, 10:8220-8228. 10.1158/1078-0432.CCR-04-0603, 15623597.
27. Whitehead TL, Kieber-Emmons T. Applying in vitro NMR spectroscopy and 1H NMR metabonomics to breast cancer characterization and detection. Prog Nucl Mag Res Sp 2005, 47:165-174.
28. Beckonert O, Monnerjahn J, Bonk U, Leibfritz D. Visualizing metabolic changes in breast-cancer tissue using 1H-NMR spectroscopy and self-organizing maps. NMR Biomed 2003, 16:1-11. 10.1002/nbm.797, 12577292.
29. Yakoub D, Keun HC, Goldin R, Hanna GB. Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients. Cancer Res 2010, 70:9129-9136. 10.1158/0008-5472.CAN-10-1566, 20884633.
30. Zhang J, Bowers J, Liu L, Wei S, Gowda GA, Hammoud Z, Raftery D. Esophageal Cancer Metabolite Biomarkers Detected by LC-MS and NMR Methods. PLoS One 2012, 7:e30181. 10.1371/journal.pone.0030181, 3264576, 22291914.
31. Wu H, Xue R, Tang Z, Deng C, Liu T, Zeng H, Sun Y, Shen X. Metabolomic investigation of gastric cancer tissue using gas chromatography/mass spectrometry. Anal Bioanal Chem 2010, 396:1385-1395. 10.1007/s00216-009-3317-4, 20012946.
32. Tiziani S, Lopes V, Günther UL. Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia 2009, 11:269-276. 2647729, 19242608.
33. Gavaghan C, Wilson I, Nicholson J. Physiological variation in metabolic phenotyping and functional genomic studies: use of orthogonal signal correction and PLS-DA. FEBS Lett 2002, 530:191-196. 10.1016/S0014-5793(02)03476-2, 12387891.
34. Postic C, Dentin R, Girard J. Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes Metab 2004, 30:398-408. 10.1016/S1262-3636(07)70133-7, 15671906.
35. Fan TW, Lane AN, Higashi RM, Yan J. Stable isotope resolved metabolomics of lung cancer in a SCID mouse model. Metabolomics 2011, 7:257-269. 10.1007/s11306-010-0249-0, 3109995, 21666826.
36. Williamson G, Day A, Plumb G, Couteau D. Human metabolic pathways of dietary flavonoids and cinnamates. Biochem Soc Trans 2000, 28:16-22.
37. Zhang S, Nagana Gowda GA, Asiago V, Shanaiah N, Barbas C, Raftery D. Correlative and quantitative 1H NMR-based metabolomics reveals specific metabolic pathway disturbances in diabetic rats. Anal Biochem 2008, 383:76-84. 10.1016/j.ab.2008.07.041, 18775407.
38. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nature Rev Cancer 2004, 4:891-899.
39. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314. 10.1126/science.123.3191.309, 13298683.
40. Eng CH, Abraham RT. Glutaminolysis yields a metabolic by-product that stimulates autophagy. Autophagy 2010, 6:968-970. 10.4161/auto.6.7.13082, 3039742, 20724823.
41. Chan EC, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, Cavill R, Nicholson JK, Keun HC. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res 2009, 8:352-361. 10.1021/pr8006232, 19063642.
42. Hasim A, Ali M, Mamtimin B, Jun-Qi MA, Qiao-Zhi LI, Abudula A. Metabonomic signature analysis of cervical carcinoma and precancerous lesions in women by 1H NMR spectroscopy. Exp Ther Med 2012, 3:945-951.
43. Yang Y, Li C, Nie X, Feng X, Chen W, Yue Y, Tang H, Deng F. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res 2007, 6:2605-2614. 10.1021/pr070063h, 17564425.
44. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2009, 29:313-324. 2809806, 19881548.
45. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010, 35:427-433. 10.1016/j.tibs.2010.05.003, 2917518, 20570523.
46. Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr 1995, 15:133-159. 10.1146/annurev.nu.15.070195.001025, 8527215.
47. Wellen KE, Lu C, Mancuso A, Lemons J, Ryczko M, Dennis JW, Rabinowitz JD, Coller HA, Thompson CB. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev 2010, 24:2784-2799. 10.1101/gad.1985910, 3003197, 21106670.
48. Yoo H, Antoniewicz MR, Stephanopoulos G, Kelleher JK. Quantifying reductive carboxylation flux of glutamine to lipid in a brown adipocyte cell line. J Biol Chem 2008, 283:20621-20627. 10.1074/jbc.M706494200, 2475696, 18364355.
49. Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H. Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 2011, 43:869-874. 10.1038/ng.890, 21804546.
50. Ippolito JE, Merritt ME, Bäckhed F, Moulder KL, Mennerick S, Manchester JK, Gammon ST, Piwnica-Worms D, Gordon JI. Linkage between cellular communications, energy utilization, and proliferation in metastatic neuroendocrine cancers. Proc Natl Acad of Sci U S A 2006, 103:12505-12510.
51. Namboodiri A, Peethambaran A, Mathew R, Sambhu PA, Hershfield J, Moffett JR, Madhavarao CN. Canavan disease and the role of N-acetylaspartate in myelin synthesis. Mol Cell Endocrinol 2006, 252:216-223. 10.1016/j.mce.2006.03.016, 16647192.
52. Fong MY, McDunn J, Kakar SS. Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One 2011, 6:e19963. 10.1371/journal.pone.0019963, 3098284, 21625518.
53. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, Nicholson JK. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2007, 2:2692-2703. 10.1038/nprot.2007.376, 18007604.
54. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, Fearnside J, Tatoud R, Blanc V, Lindon JC. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Nati Acad Sci USA 2006, 103:12511-12516.
55. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, DuGar B, Feldstein AE, Britt EB, Fu X, Chung YM. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472:57-63. 10.1038/nature09922, 3086762, 21475195.
56. Cross AJ, Pollock RA, Bingham SA. Haem, not protein or inorganic iron, is responsible for endogenous intestinal N-nitrosation arising from red meat. Cancer Res 2003, 63:2358-2360.
57. Hu Z, Deng Y, Hu C, Deng P, Bu Q, Yan G, Zhou J, Shao X, Zhao J, Li Y. 1H NMR-based metabonomic analysis of brain in rats of morphine dependence and withdrawal intervention. Behav Brain Res 2012, 231:11-19. 10.1016/j.bbr.2012.02.026, 22391120.
58. Jansson J, Willing B, Lucio M, Fekete A, Dicksved J, Halfvarson J, Tysk C, Schmitt-Kopplin P. Metabolomics reveals metabolic biomarkers of Crohn's disease. PLoS One 2009, 4:e6386. 10.1371/journal.pone.0006386, 2713417, 19636438.